P-56: Effect of Metformin and Orlistat on OvulatoryStatus in Obese PCOS Patients

Background: Polycystic Ovary Syndrome (PCOS) is the commonest cause of anovulatory infertility. Treatment modes available are numerous. The use of anti-obesity medications such as orlistat or insulin sensitizing agents such as metformin is sometimes indicated in these patients. We aimed to compare the effect of metformin vs orlistat on the hormone, lipid profile &ovulation status in obese PCOS patients. Materials and Methods: A total of 80 obese women with PCOS were recruited in this prospective randomized study to receive metformin (n=40) or orlistat (n=40). Weight, BMI, waist, serum LH, total serum testosterone & lipid profile were assessed at baseline & after 3 months. Ovulatory status was assessed after 3 months. Results: There was no significant difference between two groups regarding the ovulation rates ( p>0.05) . Treatment with both metformin & orlistat showed a significant drop in weight, waist, BMI (p